These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10531185)

  • 41. Therapy for primary pulmonary hypertension.
    McCormack D
    Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
    [No Abstract]   [Full Text] [Related]  

  • 42. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
    Stricker H; Domenighetti G; Fiori G; Mombelli G
    Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary pulmonary hypertension treated with short-term epoprostenol infusion.
    Shiota Y; Mikawa Y; Arikita H; Nakashima T; Horita N; Hiyama J; Ono T; Yamakido M
    Intern Med; 2003 Sep; 42(9):824-6. PubMed ID: 14518669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
    Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
    Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
    Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
    J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
    Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
    López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
    Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A case of severe pulmonary hypertension associated with COPD treated with epoprostenol].
    Ishikawa S; Yano S; Wakabayashi K; Tokuda Y; Kobayashi K; Ikeda T; Takeyama H
    Nihon Kokyuki Gakkai Zasshi; 2008 Aug; 46(8):660-6. PubMed ID: 18788437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).
    Humbert M; Sanchez O; Fartoukh M; Jagot JL; Sitbon O; Simonneau G
    Chest; 1998 Jul; 114(1 Suppl):80S-82S. PubMed ID: 9676646
    [No Abstract]   [Full Text] [Related]  

  • 50. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.
    Stiebellehner L; Petkov V; Vonbank K; Funk G; Schenk P; Ziesche R; Block LH
    Chest; 2003 Apr; 123(4):1293-5. PubMed ID: 12684325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment.
    Petkov V; Ziesche R; Mosgoeller W; Schenk P; Vonbank K; Stiebellehner L; Raderer M; Brunner C; Kneussl M; Block LH
    Thorax; 2001 Sep; 56(9):734-6. PubMed ID: 11514696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epoprostenol-induced hypersplenism in portopulmonary hypertension.
    Touma W; Nayak RP; Hussain Z; Bacon BR; Kudva GC
    Am J Med Sci; 2012 Nov; 344(5):345-9. PubMed ID: 22227513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.
    Plotkin JS; Kuo PC; Rubin LJ; Gaine S; Howell CD; Laurin J; Njoku MJ; Lim JW; Johnson LB
    Transplantation; 1998 Feb; 65(4):457-9. PubMed ID: 9500616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol.
    Ramsay MA; Spikes C; East CA; Lynch K; Hein HA; Ramsay KJ; Klintmalm GB
    Anesthesiology; 1999 Jan; 90(1):299-301. PubMed ID: 9915339
    [No Abstract]   [Full Text] [Related]  

  • 56. Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol.
    Rugolotto S; Beghini R; Cogo I; Sidoti G; Padovani EM; Pietrobelli A
    Pediatr Med Chir; 2013; 35(5):223-4. PubMed ID: 24516943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.
    Castro PF; Bourge RC; McGiffin DC; Benza RL; Fan P; Pinkard NB; McGoon MD
    Chest; 1998 Jul; 114(1):334-6. PubMed ID: 9674493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.
    Rich S; McLaughlin VV
    J Am Coll Cardiol; 1999 Oct; 34(4):1184-7. PubMed ID: 10520810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
    Saji T; Nakayama T; Ishikita T; Matsuura H
    Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.
    Myers SA; Ahearn GS; Angelica Selim M; Tapson VF
    J Am Acad Dermatol; 2004 Jul; 51(1):98-102. PubMed ID: 15243533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.